Development of prophylactic vaccines against HIV-1
Open Access
- 17 July 2013
- journal article
- review article
- Published by Springer Nature in Retrovirology
- Vol. 10 (1) , 72
Abstract
The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions.Keywords
This publication has 182 references indexed in Scilit:
- Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Nature, 2012
- A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challengeVaccine, 2012
- B-cell–lineage immunogen design in vaccine development with HIV-1 as a case studyNature Biotechnology, 2012
- Systems biology of vaccination for seasonal influenza in humansNature Immunology, 2011
- Expression-System-Dependent Modulation of HIV-1 Envelope Glycoprotein Antigenicity and ImmunogenicityJournal of Molecular Biology, 2010
- Rational antibody-based HIV-1 vaccine design: current approaches and future directionsCurrent Opinion in Immunology, 2010
- Defining Criteria for Oligomannose Immunogens for HIV Using Icosahedral Virus Capsid ScaffoldsChemistry & Biology, 2010
- Lytic Granule Loading of CD8+ T Cells Is Required for HIV-Infected Cell Elimination Associated with Immune ControlImmunity, 2008
- HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysisThe Lancet, 2008
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008